| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1045622464 |
| P356 | DOI | 10.2165/00003495-199447010-00002 |
| P698 | PubMed publication ID | 7510618 |
| P2093 | author name string | S L Johnston | |
| N Chanarin | |||
| P2860 | cites work | Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products | Q24681163 |
| Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist | Q28319336 | ||
| Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist | Q28322631 | ||
| Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma | Q28328440 | ||
| Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects | Q28378483 | ||
| Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and Inflammation | Q34254403 | ||
| Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects | Q34402988 | ||
| Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma | Q34484652 | ||
| Liberation of histamine and formation of lysocithin-like substances by cobra venom | Q34568156 | ||
| Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects | Q36138245 | ||
| Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma | Q36159450 | ||
| Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects | Q36161308 | ||
| Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses | Q36281989 | ||
| Leukotriene generation by eosinophils | Q36346186 | ||
| Pharmacological study of the contractile activity of leukotriene C4 and D4 on isolated human airway smooth muscle. | Q36636789 | ||
| Pharmacology of peptide leukotriene receptor antagonists | Q37518954 | ||
| Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. | Q37690942 | ||
| The potential roles of leukotrienes in bronchial asthma | Q37698215 | ||
| Mucosal inflammation in asthma | Q37946348 | ||
| Leukotrienes and airway responses. | Q39144237 | ||
| Rhinitis and asthma | Q39464652 | ||
| Platelet-activating factor as a mediator of allergic disease | Q39642730 | ||
| Perspectives in platelet-activating factor research | Q39663875 | ||
| Comparative studies of human basophils and mast cells | Q40134486 | ||
| Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases | Q40773752 | ||
| Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions | Q40841076 | ||
| Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma | Q41085264 | ||
| A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma | Q41273463 | ||
| Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics | Q41331562 | ||
| Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate | Q41850805 | ||
| Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor | Q42119720 | ||
| The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma | Q42288897 | ||
| Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4. | Q42636309 | ||
| Pharmacological profile of leukotrienes E4, N-acetyl E4 and of four of their novel omega- and beta-oxidative metabolites in airways of guinea-pig and man in vitro | Q42847351 | ||
| Release of leukotrienes in patients with bronchial asthma | Q43414768 | ||
| The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. | Q43648861 | ||
| Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo | Q44120807 | ||
| Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects | Q44241228 | ||
| Antagonism of antigen-induced contraction of guinea pig and human airways | Q44487870 | ||
| Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. | Q45227522 | ||
| Regional and time-dependent effects of inflammatory mediators on airway microvascular permeability in the guinea pig. | Q46875964 | ||
| Differential effects of calcium channel blockers on leukotriene C4- and D4-induced contractions in guinea pig pulmonary parenchymal strips. | Q53873683 | ||
| Reduced nonspecific bronchial reactivity and decreased airway response to antigen challenge in atopic asthmatic patients treated with the inhaled leukotriene D4 antagonist, L‐648,051 | Q54257704 | ||
| The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma. | Q54407306 | ||
| Bronchoalveolar lavage of allergic asthmatic patients following allergen bronchoprovocation. | Q54430446 | ||
| SLOW-REACTING SUBSTANCE OF ANAPHYLAXIS ANTAGONIST FPL 55712 IN CHRONIC ASTHMA | Q57089899 | ||
| Nebulization and selective deposition of LTD4in human lungs | Q57638511 | ||
| Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes | Q59077242 | ||
| Leukotrienes are potent constrictors of human bronchi | Q59082833 | ||
| Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin | Q67257989 | ||
| Recovery of Leukotriene E4from the Urine of Patients with Airway Obstruction | Q67491764 | ||
| Urinary Excretion of Leukotriene E4and 11-dehydro-Thromboxane B2in Response to Bronchial Provocations with Allergen, Aspirin, Leukotriene D4, and Histamine in Asthmatics | Q67491772 | ||
| Urinary leukotriene E4 excretion in exercise-induced asthma | Q67504515 | ||
| Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast—MK-0679) in asthmatic patients | Q68166533 | ||
| Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects | Q68293935 | ||
| Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist | Q68487207 | ||
| The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air | Q68613879 | ||
| Characterization of inflammatory mediator release from purified human lung mast cells | Q68796353 | ||
| Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls | Q68891371 | ||
| Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects | Q69600884 | ||
| Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects | Q69829869 | ||
| Synthesis and release of leukotriene C4 by human eosinophils | Q70157917 | ||
| Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma | Q70185502 | ||
| Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa | Q70259755 | ||
| Plasma levels of leukotrienes C4 and D4 during wheezing attack in asthmatic patients | Q70359606 | ||
| Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro | Q70469921 | ||
| Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma | Q70726803 | ||
| Leukotriene-C4 enhances mucus production from submucosal glands in canine trachea in vivo | Q71144621 | ||
| Effects of leukotriene D on the airways in asthma | Q71655873 | ||
| Bronchoconstriction produced in man by leukotrienes C and D | Q72477086 | ||
| P433 | issue | 1 | |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 12-24 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Leukotrienes as a target in asthma therapy | |
| P478 | volume | 47 |
| Q45088961 | A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis |
| Q38965222 | Boswellic Acids and Their Role in Chronic Inflammatory Diseases |
| Q33957560 | Bronchial asthma: recent advances |
| Q33725873 | Current synthetic notions on aspirin induced asthma |
| Q34453059 | Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? |
| Q30439239 | Endogenous S-nitrosoglutathione modifies 5-lipoxygenase expression in airway epithelial cells |
| Q73368962 | Glucocorticosteroids inhibit leukotriene production |
| Q73684187 | Inhibitory effects of BAY x 7195, a CYS leukotriene 1 receptor antagonist, on allergen-induced asthmatic responses |
| Q34293427 | Intracellular delivery of nanoparticles of an antiasthmatic drug |
| Q32033165 | Leukotriene D4-induced activation of smooth-muscle cells from human bronchi is partly Ca2+-independent |
| Q41582379 | Leukotriene activity modulation in asthma |
| Q40955961 | Management of asthma with zafirlukast. Clinical experience and tolerability profile |
| Q44132326 | Mediators of adenosine- and ovalbumen-induced bronchoconstriction of sensitized guinea-pig isolated airways |
| Q28376497 | Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers |
| Q43558582 | N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase |
| Q34534425 | Pharmacogenetics of asthma |
| Q28192516 | Pharmacokinetic profile of zafirlukast |
| Q40985941 | The pathogenesis of chronic obstructive pulmonary disease of horses |
| Q34745153 | Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma |
| Q41127265 | Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma |
| Q77421066 | [Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class] |
| Q51614941 | β-Boswellic acid, a bioactive substance used in food supplements, inhibits protein synthesis by targeting the ribosomal machinery. |
Search more.